Xtant Medical Holdings, Inc. (XTNT)

Market Cap	64.71M -25.1%
Revenue (ttm)	121.91M -0.3%
Net Income	1.83M
EPS	0.01
Shares Out	140.07M
PE Ratio	41.98
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	109,743
Open	0.4660
Previous Close	0.4700
Day's Range	0.4620 - 0.4799
52-Week Range	0.4380 - 0.9500
Beta	-0.12
Analysts	Strong Buy
Price Target	1.23 (+166.23%)
Earnings Date	May 13, 2026

About XTNT

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFact...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Sean Browne
• Employees: 151
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: XTNT
• Website: https://xtantmedical.com

Analyst Summary

According to 3 analysts, the average rating for XTNT stock is "Strong Buy." The 12-month stock price target is $1.23, which is an increase of 166.23% from the latest price.

Price Target

$1.23

(166.23% upside)

Analyst Consensus: Strong Buy